PYA Waltman Capital’s AbbVie ABBV Stock Holding History

PYA Waltman Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.26M	Buy	28,844 +7,641	+36%	+$1.64M	1.73%	15
2026 Q1	$4.61M	Buy	21,203 +597	+3%	+$132K	1.28%	17
2025 Q4	$4.71M	Sell	20,606 -220	-1%	-$50.1K	1.27%	16
2025 Q3	$4.82M	Buy	20,826 +451	+2%	+$91.8K	1.29%	17
2025 Q2	$3.78M	Buy	20,375 +1,871	+10%	+$348K	1.09%	22
2025 Q1	$3.88M	Buy	18,504 +51	+0.3%	+$9.91K	1.22%	18
2024 Q4	$3.28M	Buy	18,453 +402	+2%	+$73.9K	1.06%	23
2024 Q3	$3.56M	Buy	18,051 +846	+5%	+$158K	1.16%	22
2024 Q2	$2.95M	Buy	17,205 +1,117	+7%	+$185K	1.08%	24
2024 Q1	$2.93M	Buy	16,088 +282	+2%	+$48.6K	1.09%	20
2023 Q4	$2.45M	Buy	15,806 +1,939	+14%	+$283K	1.02%	23
2023 Q3	$2.07M	Buy	13,867 +3,106	+29%	+$456K	0.88%	24
2023 Q2	$1.64M	Buy	10,761 +2,869	+36%	+$421K	0.71%	24
2023 Q1	$1.26M	Buy	7,892 +2,454	+45%	+$375K	0.62%	24
2022 Q4	$879K	Buy	5,438 +934	+21%	+$143K	0.46%	25
2022 Q3	$604K	Buy	4,504 +2,556	+131%	+$367K	0.35%	27
2022 Q2	$298K	Buy	1,948 +646	+50%	+$98.7K	0.17%	34
2022 Q1	$211K	Buy	1,302 +550	+73%	+$79.9K	0.1%	43
2021 Q4	$102K	Buy	+752	New	+$88.8K	0.05%	68

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

PYA Waltman Capital's ABBV Position: Q2 2026 in Review

PYA Waltman Capital increased its AbbVie (ABBV) stake by 36% in Q2 2026, buying an estimated $1.64M and bringing the position to 28,844 shares worth $7.26M. The position accounts for 1.73% of the portfolio, ranked #15.

PYA Waltman Capital first reported a position in ABBV in Q4 2021 and has held it in 19 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

PYA Waltman Capital held 28,844 shares of AbbVie worth $7.26M as of Q2 2026.
PYA Waltman Capital bought 7,641 AbbVie shares in Q2 2026, an estimated $1.64M.
AbbVie made up 1.73% of PYA Waltman Capital's portfolio in Q2 2026, its #15 holding.
PYA Waltman Capital first reported a position in AbbVie in Q4 2021 and has held it in 19 quarters since.
4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on PYA Waltman Capital's 13F filing for Q2 2026, filed 14 Aug 2026.